Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Neuland Laboratories is a Hyderabad-based manufacturer of active pharmaceutical ingredients (APIs) and a CDMO providing custom synthesis and manufacturing solutions (CMS) for innovator pharma companies, including peptide APIs and complex small molecules. Its business mix spans generic prime APIs, specialty APIs and the higher-margin CMS segment, which has scaled sharply on commercial contracts with global innovators. It is a pure B2B player with no formulations brand business.
It is a niche Indian CDMO/peptide-API player that has emerged as a beneficiary of global supply-chain diversification away from China.
Neuland Laboratories Ltd. is a constituent of NIFTY 500, NIFTY SMALLCAP 100, NIFTY SMALLCAP 250, NIFTY SMALLCAP 50. See where it sits on the market heatmap →
Consolidated annual figures taken from Neuland Laboratories Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 283.71 | 202.74 | 233.89 |
| Book value / share (₹) | 1,453.02 | 1,181.97 | 994.31 |
| Return on equity | 19.4% | 17.1% | 23.4% |
| Return on capital employed | 21.8% | 15.0% | 28.7% |
| Operating margin | 23.9% | 17.4% | 25.9% |
| Net margin | 18.0% | 17.6% | 19.3% |
| EBITDA | ₹574 Cr | ₹323 Cr | ₹463 Cr |
| Free cash flow | ₹-49 Cr | ₹111 Cr | ₹118 Cr |
| Total debt | ₹197 Cr | ₹136 Cr | ₹83 Cr |
| Debt to equity | 0.10 | 0.09 | 0.06 |
| Interest coverage | 20.2 | 31.1 | 28.8 |
| Current ratio | 2.09 | 2.45 | 2.15 |
| Shares outstanding | 1,29,00,500 | 1,29,00,500 | 1,29,00,500 |
Open the full income statement, balance sheet and cash flow for NEULANDLAB →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.